Ramipril with felodipine
Brand names: Triapin
This is a fixed-dose oral combination of ramipril, an ACE inhibitor, with felodipine, a dihydropyridine calcium-channel blocker, used for essential hypertension where treatment with the components is appropriate.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Ramipril inhibits angiotensin-converting enzyme to reduce angiotensin-II-mediated vasoconstriction and aldosterone release, while felodipine blocks vascular L-type calcium channels to relax arterial smooth muscle, lowering blood pressure by complementary routes.
Prescribing in practice
- Avoid in pregnancy because the ACE-inhibitor component is foetotoxic; advise effective contraception in women of childbearing potential.
- ACE inhibitors can cause angioedema requiring permanent withdrawal and a persistent dry cough, with risk of hyperkalaemia and renal impairment in volume depletion, renal artery stenosis or with NSAIDs.
- Felodipine commonly causes ankle oedema, flushing and headache and undergoes interaction with grapefruit juice and CYP3A4 inhibitors, which can increase its levels and cause hypotension.
Monitoring
Monitor blood pressure, renal function and serum potassium after initiation and following any dose change.
Counselling the patient
- Avoid grapefruit juice, which can raise levels of the felodipine component.
- Seek urgent help for swelling of the face, lips, tongue or throat.
- Report a persistent dry cough and tell your doctor at once if you become pregnant.
Evidence & guidelines
Pairing a renin-angiotensin blocker with a calcium-channel blocker is supported by NICE hypertension guidance, and fixed-dose combinations improve adherence.
Reference: NICE NG136; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines